Developing a platform protocol for clinical trials evaluating interventions that target proposed mechanisms of Long COVID: RECOVER-VITAL
Zimmerman, KO; Whitley, R; O'Brien, S; et al., Clinical Trials, March 2026
View Publication on PubMed
Short Summary
The researchers leading the RECOVER-VITAL clinical trial published a paper describing the study’s design in the journal Clinical Trials. RECOVER-VITAL tested 2 different treatment durations of nirmatrelvir/ritonavir, an antiviral medication commonly used to treat mild to moderate COVID-19. The trial evaluated whether the antiviral could improve Long COVID symptoms including brain fog, dizziness, fast heart rate, fatigue, and low energy. Researchers believe these symptoms may be caused by viral persistence, which occurs when the virus that causes COVID-19 remains in the body and disrupts organs or the immune system.
The design paper outlines how the trial was organized and conducted to produce accurate results. The authors describe how the protocol was developed, as well as the development of the primary and secondary outcomes. The authors also describe the study’s broader goals: advancing understanding of Long COVID symptoms, strengthening clinical trial design, and evaluating potential treatments at a time when limited evidence was available.
This summary was prepared by the RECOVER Initiative.
Publication Details
DOI: 10.1177/17407745261422437
Abstract
Background: Long COVID, the chronic sequela of SARS-CoV-2 infection, has affected millions of people worldwide. However, its pathogenesis and treatment remain unknown. To address this critical gap, the National Institutes of Health (NIH) developed the Researching COVID to Enhance Recovery (RECOVER) Initiative that included the Viral Persistence and Reactivation, and Immune Dysregulation (RECOVER-VITAL) study as one of the first of five NIH-sponsored, integrated platform protocols to support the rigorous and rapid investigation of potential interventions for Long COVID.
Methods: Experts across academia, the NIH, and the community of patients and caregivers were brought together to design the RECOVER-VITAL protocol. We present the challenges and rationale underpinning critical components of this protocol and provide evidence for use of the platform for efficient execution of current and future Long COVID clinical trials. Facets of the RECOVER-VITAL protocol, including inclusion criteria, intervention groups, study procedures, investigation of biomarkers, and endpoints, were carefully crafted to advance the current and future science and operations of Long COVID clinical trials, particularly in the absence of existing data. The initial trial within the RECOVER-VITAL platform evaluated two durations of an antiviral drug, nirmatrelvir/ritonavir, to test the proposed etiology of viral persistence on the Long COVID symptom clusters of autonomic dysfunction, cognitive dysfunction, and exercise intolerance. The primary outcome measures were patient-reported, and secondary outcomes included performance-based measures for each of the symptom clusters of interest.
Conclusions: The RECOVER-VITAL platform protocol has substantial implications for the design and conduct of future Long COVID clinical trials.
Authors
Kanecia O Zimmerman, Richard Whitley, Sean O'Brien, David R Walt, Bruce D Levy, Christine Maughan, Marta Cerda, Rachel Olson, Lucinda Bateman, Cyndya A Shibao, Barry Make, David Knopman, Susan Redline, Leonard A Jason, Mehul S Suthar, Phillip Low, Tracy L Nolen, Craig Reist, Lisa Berdan, Lindsey R Baden
Keywords
Long COVID; PASC; RECOVER-VITAL; nirmatrelvir/ritonavir; platform protocol